IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma

ABSTRACT

Introduction: Therapeutic options for mycosis fungoides and Sézary syndrome include a variety of immunomodulatory, epigenetic, and cytotoxic options; however, none has been demonstrated to be efficacious for all patients, or to deliver deep and durable responses to the majority of patients. In this review, we examine the monoclonal antibody, IPH4102, a novel agent for the treatment of cutaneous T-cell lymphoma.

Areas covered: In this review, we examine data demonstrating the tissue specificity of KIR3DL2 receptor, which is highly expressed on the malignant cells in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. This specificity has led to the development of the agent IPH4102. Preclinical data showing efficacy of IPH4102 in vivo are outlined, as well as the results from Phase I clinical trials, which suggest that the agent is both efficacious and well-tolerated. Larger scale clinical trials are to follow.

Expert Opinion: We examine the putative benefit of IPH4102 in comparison to established agents already in the clinic, highlighting its efficacy and relative safety. We also examine possible directions that may better define the role of IPH4102 in the treatment of T-cell lymphoma in the future.

KEYWORDS:

• Cutaneous T-cell lymphoma
• IPH4102
• KIR3DL2
• monoclonal antibody
• mycosis fungoides
• Sézary syndrome

Conflicts of Interest

CVDW has no conflicts of interest.

MB is a member of Scientific Advisory Boards for Takeda, Kyowa, Innate Pharma, and Actelion.

PN has no conflicts of interest.

PKD has no conflicts of interest.

HMP is a member of the Scientific Advisory Board for Innate Pharma.

Declaration of interest

H Miles Prince is a member of the scientific advisory board for Innate Pharma, M Bagot is a member of scientific boards for Takeda, Kyona, Innate Pharma and Actelion. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

No funding to declare.